Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

MNPR Monopar Therapeutics

Price (delayed)

$32.11

Market cap

$196.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$156.65M

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of ...

Highlights
The EPS has plunged by 53% YoY but it has grown by 2.7% from the previous quarter
The net income has dropped by 118% year-on-year and by 6% since the previous quarter
The equity has contracted by 2.6% from the previous quarter

Key stats

What are the main financial stats of MNPR
Market
Shares outstanding
6.12M
Market cap
$196.36M
Enterprise value
$156.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$17.66M
Net income
-$16.57M
EBIT
-$16.57M
EBITDA
-$16.57M
Free cash flow
-$10.41M
Per share
EPS
-$4
EPS diluted
-$4
Free cash flow per share
-$1.49
Book value per share
$8.77
Revenue per share
$0
TBVPS
$7.88
Balance sheet
Total assets
$55.09M
Total liabilities
$1.49M
Debt
$0
Equity
$53.59M
Working capital
$53.58M
Liquidity
Debt to equity
0
Current ratio
36.92
Quick ratio
36.56
Net debt/EBITDA
2.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.5%
Return on equity
-55.4%
Return on invested capital
-301.3%
Return on capital employed
-30.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNPR stock price

How has the Monopar Therapeutics stock price performed over time
Intraday
7%
1 week
-8.91%
1 month
-28.58%
1 year
734.03%
YTD
45.95%
QTD
-11.81%

Financial performance

How have Monopar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.66M
Net income
-$16.57M
Gross margin
N/A
Net margin
N/A

MNPR financials

The operating income has plunged by 120% YoY and by 9% from the previous quarter
The net income has dropped by 118% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does MNPR's price correlate with its fundamentals

MNPR Price vs fundamentals

MNPR Earnings waterfall

MNPR Price vs fair value

Growth

What is Monopar Therapeutics's growth rate over time

MNPR growth chart

Valuation

What is Monopar Therapeutics stock price valuation
P/E
N/A
P/B
3.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Valuation vs average

Price to earnings (P/E)

The EPS has plunged by 53% YoY but it has grown by 2.7% from the previous quarter

Price to book (P/B)

MNPR's price to book (P/B) is 36% more than its 5-year quarterly average of 2.7 and 11% more than its last 4 quarters average of 3.3
The equity has contracted by 2.6% from the previous quarter

Price to sales (P/S)

Efficiency

How efficient is Monopar Therapeutics business performance
Monopar Therapeutics's ROIC has soared by 62% from the previous quarter
MNPR's return on equity is up by 50% year-on-year and by 35% since the previous quarter
The return on assets has grown by 40% year-on-year and by 32% since the previous quarter

Dividends

What is MNPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNPR.

Financial health

How did Monopar Therapeutics financials performed over time

Assets vs liabilities

The total liabilities has dropped by 72% since the previous quarter but it is up by 4% year-on-year
The total assets has declined by 9% since the previous quarter

Debt vs equity

The company's debt is 100% lower than its equity
The equity has contracted by 2.6% from the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.